Genpact Beat and Raised — And the Market Said "Meh, Sell It Anyway"

# Genpact Beat and Raised — And the Market Said "Meh, Sell It Anyway"

Here's a fun little puzzle for you: a company beats on earnings, beats on revenue, raises full-year guidance, posts record bookings, and grows its flagship AI segment by 24% year-over-year. What does the stock do?

It drops 5.17%.

Welcome to Genpact (G), where on August 6 the company dropped a genuinely strong Q2 — adjusted EPS of $1.00, up 13.6% year-over-year, a nice +3.09% earnings surprise, revenue growth of 7.1% to $1.34B — and the market's response the next session was to take it out back. For context, this stock's historical post-earnings move averages around -1.69%. Investors didn't just shrug this one off; they threw it down the stairs.

So what gives?

The Good Part of the Story

Genpact has rebranded itself "the Agentic Operations company," which sounds like consultant-speak until you look at the numbers behind it. Advanced Technology Solutions — the AI-and-automation arm — grew net revenue 24% year-over-year to $363M. That's not a rounding error; that's the whole growth story. Management raised full-year EPS guidance to $4.088+, comfortably above the Street's $3.990 consensus. Bookings hit records. Operating margins are healthy at 15.4%, gross margins 37.7%, and the balance sheet carries a solid 2.00 current ratio. This is not a company falling apart.

And the valuation, depending on whose spreadsheet you trust, looks cheap. Some sources peg the forward P/E around 7.6x with a PEG near 0.65 — numbers that, if accurate, mean the market is pricing Genpact like a melting ice cube rather than a company growing its highest-margin segment by nearly a quarter every year.

The Catch

Here's where I have to be the annoying voice in the room: not everyone agrees on those numbers. Other data sources show a forward P/E north of 18x and a PEG closer to 1.0 — which is a completely different stock, valuation-wise. When your bull case leans hard on "it's dirt cheap" and the multiple people are citing swings from 6.4x to 18.3x depending on the source, that's not a rounding error, that's a credibility problem. Pick your favorite number and you can make Genpact look like a steal or a stock that's merely fairly priced. I'd want more clarity before betting size on the "cheap" argument alone.

Then there's the deliberate part of the story nobody wants to say out loud on the earnings call: Genpact is intentionally walking away from non-strategic, legacy business lines. That's smart housekeeping for the long-term AI pivot, but it also means headline revenue growth gets throttled in the near term even while ATS is humming. The market may have looked past the EPS beat and focused instead on: "wait, is total growth actually decelerating here?" That's a plausible explanation for a 5%+ drubbing that a beat-and-raise normally wouldn't produce.

Add in an Altman Z-score of 2.98 — solidly in the "grey zone," not a disaster but not a fortress either — a debt/equity ratio north of 54x, and a Q2 free cash flow that actually went negative (-$55M) on higher capex, and you've got a company that's transitioning, not coasting.

Where That Leaves Us

The stock closed near $34.29, sitting between support around the $32 SMA20 and resistance near $36 SMA50, with analyst targets clustering around $38–$39 and a bull case stretching to $42. That's real upside if the ATS growth story holds up and the market eventually stops treating every good quarter like bad news.

But "sell the news" reactions after clean beats are usually the market telling you something the headline numbers aren't. My read: this isn't a stock to chase on the dip out of spite. It's a stock to watch for confirmation — a reclaim of that $32 support with actual volume behind it, or better yet, a Q3 print (due around November 5, consensus EPS $1.04) that shows ATS growth holding at or near 24% rather than fading.

Genpact might well be cheap. It might also just be a company in the messy middle of a transition that the market hasn't decided how to price yet. Those are two very different trades — don't confuse conviction in the AI pivot with conviction in the multiple. Wait for the tape to agree with the thesis before you do.